Fludara
Phase 1Small molecule
Fludara is one of 132 small molecule programs targeting Neuroblastoma. It is currently in Phase 1.
4
Indications
6
Total Trials
5
Active Trials
131
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
258 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Empliciti
Bristol-Myers SquibbPhase 3
Belamaf
GSKPhase 3
Keytruda
Merck & Co.Phase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Neulasta
AmgenPhase 3
Vepesid
AAvyxa
Phase 3
Cytosar
TevaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelodysplastic Syndrome1 trial
Multiple Myeloma1 trial
Neuroblastoma1 trial
3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Active, not recruiting·—·Phase 1·NCT01822652·11 enrolled
Pediatric Solid Tumors1 trial
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Active, not recruiting·—·Phase 1·NCT02932956·10 enrolled
1 more indication
Liver Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fludara. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCelyad Oncology SA